Retour au classement

Reckitt Benckiser Group plc (RBGPF)

NEUTRAL
Consumer DefensiveHousehold & Personal ProductsUnited Kingdom

Fondamental

52

Prix

$5150.00

Capitalisation boursière

$32.48B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.

Comment l'entreprise gagne de l'argent

Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.

Avantage concurrentiel

Marque · Étroit

Reckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.

Ce qui stimule la demande

Défensif

Most of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.

Les arguments en faveur

Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.

Les arguments contre

Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.

Written by the editors, published on 18 août 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilan & Liquidités

Chiffre d'affaires

$13.35B

12 derniers mois jusqu'au dernier trimestre publié — estimation à partir de ratios par action

Résultat net

$2.81B

12 derniers mois jusqu'au dernier trimestre publié — estimation à partir de ratios par action

Flux de trésorerie libre

$3.09B

Capitaux propres totaux

$5.67B

Passif total

$10.25B

Ratio de liquidité général

0.59

Couverture des intérêts

-

Dette/EBITDA

2.86

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

Surévalué

Juste valeur

$2156.36

Prix actuel

$5150.00

Marge de sécurité

-138.8%

Fourchette de juste valeur

$1401.63 - $2911.08

Méthodes d'estimation

Analyst Target:$6223.26
DCF:$178.69
PE-based:$61.40
Graham Growth:$220.37
EPV:$42.58
Consensus des analystes:Achat fort (22B / 7H / 0S)
Dernière surprise sur les résultats:-1.27%

Indicateurs de valorisation

Ratio P/E

1169.99

ROE

48.0%

Ratio P/B

580.17

P/FCF

1049.76

Marge brute

59.6%

ROIC

12.3%

Radar de rentabilité

Value Creation (Economic Moat)

ROIC

12.3%

WACC

8.5%

ROIC − WACC

+3.8 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Critères d'analyse fondamentale

Réussi (10)

  • ROIC 12.3%
  • Gross Margin 59.6%
  • Debt/Equity ratio
  • Operating Margin 28.5%
  • Positive Free Cash Flow
  • Debt/EBITDA
  • ROE 42.9%
  • Analyst Consensus 76% Buy
  • PEG Ratio 0.47
  • Net Margin Trend 22.4% vs 10.1%

Échoué (11)

  • Price CAGR -3.27%
  • P/FCF 1049.76
  • P/B Ratio 580.17
  • CapEx intensity
  • Current Ratio
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Revenue Growth 5Y 0.3%
  • Earnings Surprise avg 2.4%
  • Earnings Quality (OCF/NI) 0.66
  • Piotroski F-Score 1/9

Indisponible (6)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Share Dilution (missing shares data)

Score F de Piotroski

1/9

Préoccupations financières sérieuses

score
criteria

Qualité des bénéfices

0.66

Modérée : certain écart entre profits et trésorerie

Dilution du capital

-

Rachat d'actions. Favorable aux actionnaires

Gouvernance

Équipe dirigeante

NomTitreÂge
Mr. Kristoffer Loe LichtCEO & Executive Director49
Ms. Shannon Sue EisenhardtCFO & Executive Director51
Mr. Nicholas James Ashworth C.F.A.Senior Vice President of Investor Relations-
Ms. Catheryn O'RourkeSenior VP, General Counsel & Company Secretary52
Ms. Sheila RedzepiChief Communications & Corporate Affairs Officer46
Mr. Ranjay RadhakrishnanChief Human Resources Officer54
Mr. Jerome LemairePresident North America51
Ms. Angela Naef Ph.D.Chief Research & Development Officer49
Ms. Susan SholtisPresident of Nutrition58
Dr. Alessio Fasano M.D.Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business-

Risque d'audit

4

Risque du conseil

2

Risque de rémunération

3

Risque droits des actionnaires

1

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Latest News

Recent headlines for RBGPF, sourced from Markets Gazette.

No recent news for RBGPF.